Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,418.00GBp
12:04pm EDT
Change (% chg)

-29.00 (-0.65%)
Prev Close
4,447.00
Open
4,426.00
Day's High
4,800.00
Day's Low
4,388.00
Volume
1,656,374
Avg. Vol
2,497,092
52-wk High
5,585.07
52-wk Low
3,996.00

Latest Key Developments (Source: Significant Developments)

Perrigo announces final FDA approval and settlement for the store brand OTC equivalent of Nexium 24hr capsules
9:01am EDT 

Aug 21 (Reuters) - Perrigo Company Plc :Perrigo announces final FDA approval and settlement for the store brand OTC equivalent of Nexium 24hr capsules.‍Received final approval from U.S. Food & drug administration for store brand OTC equivalent of nexium 24hr capsules​.Says ‍product will be packaged and marketed as store brand or retailer 'own label' brand​.‍Reached settlement of patent litigation with Astrazeneca allowing store brand OTC equivalent of Nexium 24hr capsules to launch in late Sept..  Full Article

Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of PDX models
8:30am EDT 

Aug 21 (Reuters) - Champions Biotechnology Inc :Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of patient-derived xenograft (PDX) models.Champions Biotechnology Inc- ‍cohorts of PDX models will be used in AstraZeneca's Oncology research and development programs in breast and lung cancer​.  Full Article

Ethris announces five-year research collaboration with Astrazeneca
2:39am EDT 

Aug 21 (Reuters) - ETHRIS GMBH::ANNOUNCED A FIVE-YEAR STRATEGIC RESEARCH COLLABORATION WITH ASTRAZENECA AND ITS GLOBAL BIOLOGICS RESEARCH AND DEVELOPMENT ARM, MEDIMMUNE.TO RECEIVE EUR 25 MLN UPFRONT PLUS RESEARCH FUNDING, ELIGIBLE FOR FUTURE R&D MILESTONES,INCLUDING SALES RELATED ROYALTIES UPON COMMERCIALISATION.ASTRAZENECA,MEDIMMUNE TO HAVE OPTION TO TAKE EXCLUSIVE WORLDWIDE LICENSES UPON COMPLETION OF RESEARCH PLAN FOR EACH TARGET WITHIN COLLABORATION.  Full Article

AstraZeneca hires two immuno-oncology experts
Monday, 31 Jul 2017 08:30am EDT 

July 31 (Reuters) - AstraZeneca Plc ::‍Jean-Charles Soria joins Medimmune, co's global biologics research and development arm, as senior vice president, head of oncology innovative medicines.Geoffrey Kim appointed head oncology strategic combinations at AstraZeneca​.  Full Article

CEO believes AstraZeneca can continue to secure dividend
Thursday, 27 Jul 2017 09:26am EDT 

July 27 (Reuters) - AstraZeneca CEO Pascal Soriot tells analysts::Believes company can continue to secure the dividend.  Full Article

Roche says real demand, not stocking, drives Ocrevus sales
Thursday, 27 Jul 2017 08:30am EDT 

July 27 (Reuters) - Roche Holding AG :Roche ceo says no doubt perjeta will be a substantial growth driver.Roche drugs head says astrazeneca lung cancer study failure doesn't change roche's plans.Roche drugs head says sees no risk to regulatory approvals from aphinity study.Roche drugs head says ocrevus sales reflect demand, not major stocking.Roche ceo says bullish about cancer immunotherapy, want to play leading role.  Full Article

AstraZeneca's lung cancer drug succeeds late-stage trial
Thursday, 27 Jul 2017 07:23am EDT 

July 27 (Reuters) - Astrazeneca Plc -:Tagrisso® (osimertinib) significantly improves progression-free survival in the phase iii flaura trial for lung cancer.Astrazeneca plc - ‍tagrisso met primary endpoint​.  Full Article

Valeant announces U.S. launch of siliq injection
Thursday, 27 Jul 2017 07:22am EDT 

July 27 (Reuters) - Astrazeneca Plc ::Valeant announces U.S. launch of siliq (brodalumab) injection.Valeant says that its dermatology unit will be renamed Ortho Dermatologics, effective immediately.Valeant says under new senior leadership team lead by Bill Humphries, executive vice president and company group chairman, Ortho Dermatologics.Valeant - ‍siliq has a black box warning for "risks of suicidal ideation and behavior​".  Full Article

AstraZeneca CEO: proud to lead AZ, no comment on rumours of move to Teva
Thursday, 27 Jul 2017 03:23am EDT 

July 27 (Reuters) - AstraZeneca CEO Pascal Soriot tells reporters::Not commenting on speculation about his position but proud to be CEO of AZ.Looks forward to continuing to lead AZ team.Nothing further to add, following rumours he might be leaving to join Teva.Further company coverage: AZN.L.  Full Article

Astrazeneca says establish strategic oncology collaboration with Merck
Thursday, 27 Jul 2017 02:06am EDT 

July 27 (Reuters) - Astrazeneca Plc ::ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION.ASTRAZENECA PLC - ASTRAZENECA AND MERCK WILL INDEPENDENTLY DEVELOP AND COMMERCIALISE LYNPARZA AND POTENTIAL MEDICINE SELUMETINIB IN COMBINATIONS WITH COMPANIES' RESPECTIVE.MERCK WILL PAY CO UP TO $8.5 BILLION IN TOTAL CONSIDERATION.ASTRAZENECA- COS TO SHARE DEVELOPMENT, COMMERCIALISATION COSTS FOR LYNPARZA, SELUMETINIB MONOTHERAPY, NON-PD-L1/PD-1 COMBINATION THERAPY OPPORTUNITIES.ASTRAZENECA PLC - MERCK WILL FUND ALL DEVELOPMENT AND COMMERCIALISATION COSTS OF KEYTRUDA IN COMBINATION WITH LYNPARZA OR SELUMETINIB.ASTRAZENECA PLC - ASTRAZENECA WILL FUND ALL DEVELOPMENT AND COMMERCIALISATION COSTS OF IMFINZI IN COMBINATION WITH LYNPARZA OR SELUMETINIB.ASTRAZENECA PLC - ASTRAZENECA WILL CONTINUE TO MANUFACTURE LYNPARZA AND SELUMETINIB.UNDER TERMS OF AGREEMENT, ASTRAZENECA ANTICIPATES APPROXIMATELY $1 BILLION TO BE RECORDED UNDER EXTERNALISATION REVENUE IN 2017.COLLABORATION AGREEMENT WAS COMPLETED UPON SIGNING ON 26 JULY 2017.ASTRAZENECA PLC - MERCK WILL PAY ASTRAZENECA UP TO $8.5 BILLION IN TOTAL CONSIDERATION.  Full Article

BRIEF-Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of PDX models

* Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of patient-derived xenograft (PDX) models